SAFE-T CONSORTIUM (IMI-JU) : Translational Safety Biomarkers Initiative

SAFE-T IMISAFE-T is a Firalis-initiated public-private partnership, focusing on translational safety biomarkers, established under “Innovative Medicines Initiative (IMI)” framework.

Consortium has 28 partners, a majority of which are industry partners such as AstraZeneca, GSK, Novartis, Pfizer and Roche (view all partners).For more information on SAFE-T, (one of the largest biomarker initiatives ever) visit project’s public  web-site: